{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:51:04Z","timestamp":1649076664082},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.medcli.2013.04.042","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T12:16:15Z","timestamp":1373458575000},"page":"6-12","source":"Crossref","is-referenced-by-count":1,"title":["Impacto de CYP2C19*2 en la reactividad plaquetar en pacientes con s\u00edndrome coronario agudo tratados con clopidogrel"],"prefix":"10.1016","volume":"143","author":[{"given":"Pedro","family":"Cano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Consuegra-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Conesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Torres-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Jaulent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Dau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Pic\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.04.042_bib0005","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1592\/phco.28.8.992","article-title":"Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: Prevalence of related drug use","volume":"28","author":"Frueh","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medcli.2013.04.042_bib0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1373\/clinchem.2011.165829","article-title":"Clopidogrel and CYP2C19 testing: Ready for clinical prime time?","volume":"58","author":"Hulot","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.medcli.2013.04.042_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.medcli.2010.09.015","article-title":"Nueva era en la terapia antiplaquetar basada en los resultados de ensayos cl\u00ednicos recientes","volume":"137","author":"P\u00e1ramo","year":"2011","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.04.042_bib0020","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2013.04.042_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.042_bib0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2013.04.042_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.042_bib0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2013.04.042_bib0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2013.04.042_bib0050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2013.04.042_bib0055","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"Frelinger","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2013.04.042_bib0060","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2013.04.042_bib0065","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2013.04.042_bib0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ahj.2012.10.013","article-title":"Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention","volume":"165","author":"Park","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2013.04.042_bib0075","doi-asserted-by":"crossref","first-page":"d4588","DOI":"10.1136\/bmj.d4588","article-title":"Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis","volume":"343","author":"Bauer","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2013.04.042_bib0080","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2013.04.042_bib0085","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2013.04.042_bib0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ahj.2010.10.036","article-title":"Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention","volume":"161","author":"Ko","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2013.04.042_bib0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcin.2009.10.024","article-title":"High residual platelet reactivity after clopidogrel: Extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention","volume":"3","author":"Mangiacapra","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.medcli.2013.04.042_bib0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJMra0912134","article-title":"Myocardial infarction due to percutaneous coronary intervention","volume":"364","author":"Prasad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.04.042_bib0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.medcli.2013.04.042_bib0110","unstructured":"The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Disponible en: http:\/\/www.cypalleles.ki.se\/"},{"key":"10.1016\/j.medcli.2013.04.042_bib0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/oxfordjournals.aje.a116813","article-title":"Simulation study of confounder-selection strategies","volume":"138","author":"Maldonado","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.medcli.2013.04.042_bib0120","unstructured":"International Hapmap Project. Disponible en: http:\/\/hapmap.ncbi.nlm.nih.gov\/index.html.en"},{"key":"10.1016\/j.medcli.2013.04.042_bib0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.recesp.2011.07.013","article-title":"Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome","volume":"65","author":"Tello-Montoliu","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.medcli.2013.04.042_bib0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/hrt.2011.227652","article-title":"Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel","volume":"98","author":"Zabalza","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.medcli.2013.04.042_bib0135","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.medcli.2013.04.042_sbref0140a","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehs059","article-title":"The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The CHARISMA genetics study","volume":"33","author":"Bhatt","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.medcli.2013.04.042_sbref0140b","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1538-7836.2012.04756.x","article-title":"Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: A systematic review and meta-analysis","volume":"10","author":"Reny","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2013.04.042_bib0145","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.amjcard.2011.11.049","article-title":"Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting","volume":"109","author":"Toma","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.medcli.2013.04.042_bib0150","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/hrt.2010.220509","article-title":"Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting","volume":"97","author":"Bouman","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.medcli.2013.04.042_bib0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jcin.2012.09.013","article-title":"High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study","volume":"6","author":"Leoncini","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.medcli.2013.04.042_bib0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/09537104.2010.512402","article-title":"Statins have an early antiplatelet effect in patients with acute myocardial infarction","volume":"22","author":"Matetzky","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.medcli.2013.04.042_bib0165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1160\/TH08-06-0385","article-title":"No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance","volume":"101","author":"Malmstr\u00f6m","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.medcli.2013.04.042_bib0170","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.thromres.2011.05.008","article-title":"The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent","volume":"128","author":"Gremmel","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.medcli.2013.04.042_bib0175","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313003527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:15:12Z","timestamp":1563408912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313003527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0025775313003527"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.04.042","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}